Docetaxel is under clinical development by Plus Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Docetaxel’s likelihood of approval (LoA) and phase transition for Non-Small Cell Lung Cancer took place on 18 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 18 Feb 2022 decreased Docetaxel’s LoA and PTSR for Prostate Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Docetaxel Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Docetaxel overview

docetaxel (ATI-1123) is under development for the treatment of solid tumors such as breast cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer, thyroid cancer, gastric cancer, uterine cancer, urachal cancer, cervical cancer, prostate cancer, soft-tissue sarcoma and melanoma. ATI-1123 is with a brand name DocePlus is administered through intravenous route and by drip. It acts by targeting beta tubulin. It is developed based on protein stabilized liposome (PSL) nanotechnology.

It was also under development for the treatment of small cell lung cancer.

Plus Therapeutics overview

Plus Therapeutics, formerly Cytori Therapeutics Inc is a developmental-stage pharmaceutical company, which focuses on the discovery, development, and manufacturing of complex and innovative treatments for patients with cancer and other life-threatening diseases. Its pipeline of candidate drug products includes Doceplus, a patented albumin-stabilized Pegylated liposomal formulation of docetaxel; Doxoplus, a complex, injectable, generic Pegylated liposomal formulation of doxorubicin; BMEDA-chelated rhenium nanoliposome (RNL); and a co-encapsulated, doxorubicin and rhenium nanoliposome (DRNL). It uses a proprietary nanotechnology platform to reformulate and improve conventional chemotherapeutics. Plus Therapeutics is headquartered in Irvine, Texas, the US.

Quick View Docetaxel LOA Data

Report Segments
  • Innovator
Drug Name
  • Docetaxel
Administration Pathway
  • Intravenous
  • Parenteral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.